产品
编 号：F611269
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 780758-10-3
产品详情
生物活性：
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
体外研究：
Nimotuzumab (10 μg/mL；24 小时) 诱导 NK 细胞上 CD16 的显著下调。 当与 NK：DC：HNSCC 细胞共培养时，Nimotuzumab (10 μg/mL；48 小时) 诱导 DC 上 PD-L1 分子的上调。 Nimotuzumab 的内在特性需要二价结合 (即与两个抗体臂同时结合两个靶点) 以稳定附着于细胞表面，这导致 Nimotuzumab 选择性地结合表达中度至高水平 EGFR 的细胞。
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
体外研究：
Nimotuzumab (10 μg/mL；24 小时) 诱导 NK 细胞上 CD16 的显著下调。 当与 NK：DC：HNSCC 细胞共培养时，Nimotuzumab (10 μg/mL；48 小时) 诱导 DC 上 PD-L1 分子的上调。 Nimotuzumab 的内在特性需要二价结合 (即与两个抗体臂同时结合两个靶点) 以稳定附着于细胞表面，这导致 Nimotuzumab 选择性地结合表达中度至高水平 EGFR 的细胞。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备